Medpace (MEDP) closed at $443, up 1.84% from the previous day, outperforming the S&P 500, which rose by 0.55%. The company is set to announce its earnings on July 22, 2024, with analysts predicting earnings of $2.52 per share, a 30.57% increase year-over-year.

Analysts also estimate Medpace’s revenue to be $529.73 million, a 14.94% rise from the previous year. The Zacks Consensus Estimates anticipate full-year earnings of $11.29 per share and revenue of $2.17 billion, showing increases of 27.14% and 14.92%, respectively.

With a Zacks Rank of #2 (Buy), Medpace has a Forward P/E ratio of 38.55, higher than the industry average of 19.68. Its PEG ratio of 2.15 is above the industry average of 1.53. The Medical Services industry, where Medpace belongs, is in the top 41% of all industries according to Zacks Industry Rank.

Investors should keep an eye on analyst revisions for Medpace, as they can impact stock price performance. The Zacks Rank system, with a track record of outperformance, rates Medpace as a Buy. Utilize Zacks.com to monitor stock metrics and industry rankings for informed decisions.

Read more at Nasdaq: Medpace (MEDP) Beats Stock Market Upswing: What Investors Need to Know